InspireMDNSPR +9.92%35 Days Payable is 54.01 as of Mar. 2026, which is 26% below its 10-year median of 72.54. GuruFocus rates NSPR with a GF Score™ of 35/100 and a GF Value™ of $1.78 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 795 Medical Devices & Instruments companies, InspireMD ranks better than 55.35% on this metric.
InspireMD's average Accounts Payable for the
three
months ended in Mar. 2026 was $1.60 Mil. InspireMD's Cost of Goods Sold for the
three
months ended in Mar. 2026 was $2.71 Mil.
Hence, InspireMD's Days Payable for the
three
months ended in Mar. 2026 was 54.01.
The historical rank and industry rank for InspireMD's Days Payable or its related term are showing as below:
NSPR'
s Days Payable Range Over the Past 10 Years
Min: 55.08 Med: 72.54 Max: 115.08
Current: 76.77
During the past 13 years, InspireMD's highest Days Payable was 115.08. The lowest was 55.08. And the median was 72.54.
NSPR's Days Payable is ranked better than 55.35% of 795
companies
in the Medical Devices & Instruments industry
Industry Median: 68.07
vs NSPR: 76.77
InspireMD's Days Payable
declined
from Mar. 2025 (109.95) to Mar. 2026 (54.01).
It may suggest that InspireMDaccelerated paying its suppliers.
InspireMD Days Payable Related Terms
InspireMD Days Payable Historical Data
* Premium members only.
The historical data trend for InspireMD's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, InspireMD's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
InspireMD Days Payable vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, InspireMD's Days Payable distribution charts can be found below:
* The bar in red indicates where InspireMD's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
InspireMD's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
InspireMD (NSPR) has a Days Payable of 54.01 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on InspireMD and its competitors. This is 26% below median its historical median of 72.54. Over the past decade, InspireMD's Days Payable has ranged from 55.08 to 115.08. According to the industry distribution chart, InspireMD ranks #355 out of 795 companies in the Medical Devices & Instruments industry, placing it in the top 44.7%.
Is InspireMD's Days Payable too high?
InspireMD's current Days Payable of 54.01 is 26% below median its 10-year median of 72.54. Over the past 10 years, this metric has ranged from a low of 55.08 to a high of 115.08. The Medical Devices & Instruments industry median Days Payable is 68.07. InspireMD's value of 54.01 is 20.7% below this industry median. Based on the distribution chart, InspireMD ranks #355 out of 795 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, InspireMD has a GF Score™ of 35/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does InspireMD's Days Payable compare to TELA and BDMD?
According to the Medical Devices & Instruments industry distribution chart, InspireMD ranks #355 out of 795 companies for Days Payable. This puts InspireMD in the upper half of its industry. The industry median Days Payable is 68.07. InspireMD's value of 54.01 is 20.7% below this benchmark. Historically, InspireMD's own Days Payable has ranged from 55.08 to 115.08 over the past decade. While the company's 10-year median is 72.54 vs. the industry median of 68.07, InspireMD has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Devices & Instruments company?
The median Days Payable among Medical Devices & Instruments companies is 68.07, based on 795 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. InspireMD's current Days Payable of 54.01 is 20.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on InspireMD and its competitors. For the Medical Devices & Instruments industry, the median Days Payable is 68.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. InspireMD's current Days Payable is 54.01, which is 26% below median its own 10-year median of 72.54. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is InspireMD stock overvalued right now?
Based on GuruFocus' analysis, InspireMD (NSPR) is currently considered Possible Value Trap. The stock's GF Value™ is $1.78, compared to a current price of $0.71 — trading 60% below its estimated fair value. The current Days Payable is 54.01, which is 26% below median its 10-year median of 72.54 and 20.7% below the Medical Devices & Instruments industry median of 68.07. InspireMD's overall GF Score™ is 35/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For InspireMD (NSPR), the current Days Payable is 54.01 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is InspireMD (NSPR) Overvalued in 2026?
Based on GuruFocus' analysis, InspireMD stock appears to be undervalued.
The current stock price of $0.71 is trading 60% below its estimated GF Value™ of $1.78.
GuruFocus considers InspireMD to be Possible Value Trap.
Key valuation signals for NSPR:
Days Payable: 54.01 (26% below median its 10-year median of 72.54)
GF Value™: $1.78 vs. price of $0.71 (60% below fair value)
Industry Position: 20.7% below the Medical Devices & Instruments median (#355 of 795)
No single metric tells the full story. See the NSPR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
InspireMD Inc is a United States-based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System. It generates the majority of the revenue from the sales of CGuard EPS, which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The Company has one operating and reporting segment that develops, manufactures, and markets products for the treatment of carotid artery disease and other vascular diseases, including the Company's proprietary CGuard stent platform.
35GF Score
Get the complete analysis for NSPR
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSPR has been successfully added to your 
